# Pharmacokinetic and Safety Study of Metronidazole Oral Suspension in Pediatric Patients With Anaerobic Bacterial Infection

> **NCT07146217** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Saptalis Pharmaceuticals LLC** · enrollment: 30 (estimated)

## Conditions studied

- Bacterial Infections

## Interventions

- **DRUG:** Likmez® (metronidazole) Oral Suspension

## Key facts

- **NCT ID:** NCT07146217
- **Lead sponsor:** Saptalis Pharmaceuticals LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08
- **Primary completion:** 2026-07
- **Final completion:** 2026-10
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-08-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07146217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07146217, "Pharmacokinetic and Safety Study of Metronidazole Oral Suspension in Pediatric Patients With Anaerobic Bacterial Infection". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07146217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*